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Abstract  
Background:  Conflicting data exist on the impact of dietary and circulating levels of 
branched chain amino acids (BCAA) on cardiometabolic health and it is unclear to what 
extent these relations are mediated by genetics.   
Methods: In a cross-sectional study of 1997 female twins we examined associations between 
BCAA intake, measured using food frequency-questionnaires, and a range of markers of 
cardiometabolic health, including DXA-measured body fat, blood pressure, HOMA-IR, high-
sensitivity C-reactive protein (hs-CRP) and lipids.  We also measured plasma concentrations 
of BCAA and known metabolites of amino acid metabolism using untargeted mass 
spectrometry.  Using a within-twin design, multivariable analyses were used to compare the 
associations between BCAA intake and endpoints of cardiometabolic health, independently 
of genetic confounding.   
Results:  Higher BCAA intake was significantly associated with lower HOMA-IR (-0.1, P-
trend 0.02), insulin (-0.5 µU/mL, P-trend 0.03), hs-CRP -0.3 mg/L, P-trend 0.01), systolic 
blood pressure (-2.3 mm Hg, P-trend 0.01) and waist-to-height ratio (-0.01, P-trend 0.04), 
comparing extreme quintiles of intake.  These associations persisted in within-pair analysis 
for monozygotic twins for insulin resistance (P<0.01), inflammation (P=0.03), and blood 
pressure (P=0.04) suggesting independence from genetic confounding.  There were no 
association between BCAA intake and plasma concentrations, although two metabolites 
previously associated with obesity were inversely associated with BCAA intake (alpha-
hydroxyisovalerate and trans-4-hydroxyproline).    
Conclusions:  Higher intakes of BCAA were associated, independently of genetics, with 
lower insulin resistance, inflammation, blood pressure and adiposity-related metabolites.  The 
BCAA intake associated with our findings are easily achievable in the habitual diet. 
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Introduction  
Conflicting results have been reported on the relationship between branched chain amino 
acids (BCAA), which includes the essential amino acids leucine, isoleucine and valine, and 
cardiometabolic health.  Higher fasting plasma concentrations of BCAA have been associated 
with an increased risk of developing type 2 diabetes and insulin resistance in both rodent 
models and humans (1) with several longitudinal studies observing that higher circulating 
levels of BCAA are associated with a threefold higher risk of type 2 diabetes and 1.3-fold 
higher risk of metabolic syndrome (2, 3). Together these data have led to the suggestion that 
increased blood levels are predictive of future insulin resistance or type 2 diabetes.   
 
In sharp contrast, BCAA supplementation and diets rich in BCAA intake have been shown to 
be beneficial for metabolic health (regulation of body weight and glucose homeostasis), 
especially in rodent models.  Specifically, increasing leucine intake in mice fed a high-fat diet 
resulted in a 32% reduction in weight gain, a 25% decrease in adiposity and a 53% decrease 
in LDL-cholesterol concentrations independent of adiposity (4).  Improved body weight, 
glucose tolerance and insulin sensitivity were also observed in mice fed a BCCA-rich protein 
source (whey protein isolate) (5).  A previous small-scale study in 296 males reported higher 
BCAA intake (0.03 g/kg body weight) was associated with reduced weight (13.8 kg), total 
body fat (4.5%), insulin concentrations (2.1 µU/mL), diastolic blood pressure (3.4 mm Hg) 
and a 47% lower prevalence of metabolic syndrome (6).   
 
One proposed explanation for these conflicting findings is that circulating BCAA are a 
biomarker of impaired insulin action, rather than a causative factor of insulin resistance, via 
activation of mammalian target of rapamycin complex 1 signalling or accumulation of 
mitotoxic metabolites that subsequently cause mitochondrial dysfunction and apoptosis 
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associated with type 2 diabetes (1).  Direct and indirect mechanisms for the positive effects of 
BCAA intake have been suggested including direct effects on hypothalamus derived 
processes associated with satiety and body weight and enhanced insulin-stimulated AKT 
phosphorylation and glucose uptake related to improved insulin sensitivity and glucose 
metabolism (7, 8).         
 
To our knowledge there are no comprehensive population based studies examining the 
associations between BCAA intake and parameters of adiposity and cardiometabolic health 
and no studies utilizing a twin model to explore the relative contributions of diet and genetics 
and reduce confounding.  We firstly examined the associations between intake and 
circulating levels of BCAA and then investigated the relationship between intakes and a 
range of parameters of metabolic health, including obesity, insulin resistance, inflammation 
and blood pressure, using this unique approach. On the basis of previous research, we 
expected that participants with higher BCAA intake would have lower adiposity and healthier 
parameters of cardiometabolic health; additionally we hypothesized that the associations 
would remain significant within monozygotic (MZ) and dizygotic (DZ) twin-pairs, 
suggesting a lack of genetic confounding.  
 
Methods  
Study population 
Participants included in these analyses were twins enrolled in the TwinUK cohort (9).  The 
participants were not selected for particular diseases or traits and were unaware of the 
specific hypotheses being tested.  The cohort has previously shown to be representative of the 
general UK population in terms of disease- and lifestyle-related characteristics, including diet 
(10, 11).  In this study we included female twins, aged 18-76 y, who had completed a food 
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frequency questionnaire (FFQ) and attended a clinical assessment for cardiometabolic risk 
factors between 1996 and 2000.  In total, 4181 unique participants completed a FFQ, of 
which 22% (n=919) were either incomplete (>10 food items were left blank) or participants 
reported implausible energy intake (defined as the ratio of energy intake to estimated basal 
metabolic rate falling ≥2SD from the population mean).  Of the 3262 participants who 
completed a valid FFQ, 61% (n=1997) attended for a relevant clinical assessment.  Although 
3299 participants had metabolomics data, clinical data were unavailable for 2360 of these 
participants, leaving us with 28% (n=939) to include in the current analyses.  Although the 
sample size was fixed before the start of the study a formal power calculation revealed that a 
moderate association with blood pressure of 2 mm Hg (α = 0.05, 95% power) would require 
913 participants in these multivariate analyses.  The study was approved by the St. Thomas’ 
Hospital Research Ethics committee and all subjects provided informed written consent. 
 
Assessment of cardiometabolic biomarkers  
Anthropometric measurements were made in light clothing, height was measured using a 
wall-mounted stadiometer to the nearest 0.5 cm, weight (light clothing only) was measured 
with digital scales to the nearest 0.1 kg and waist circumference (cm) was measured at the 
level midway between the lower rib margin and the iliac crest.  These data were used to 
derive BMI (kg/m2) and waist to height ratio (WHtR).  Body fat was measured by dual-
energy X-ray absorptiometry using standard protocols (QDR-2000W, Hologic, 
Massachusetts, USA) and percentage body fat was calculated as (body fat (kg)/ total body 
mass (kg))*100.  Overweight was defined if BMI was greater than 25 kg/m2 and abdominal 
obesity if WHtR ratio was greater than 0.5.  Data on WHtR and body fat was available for 
1828 (92%) and 1792 (90%) of the study population, respectively. 
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Serum samples obtained from venous blood samples were collected between 8-10 am after an 
overnight fast.  Insulin was measured by immunoassay (Abbott Laboratories Ltd., 
Maidenhead, UK), and glucose using an enzymatic colorimetric assay (Ektachem 700 
multichannel analyzer, Johnson and Johnson Clinical Diagnostic Systems, Amersham, UK). 
HOMA-IR was calculated according to the formula: fasting insulin x fasting glucose /22.5.  
Insulin resistance was defined if HOMA-IR was ≥ 2.5 arbitrary units.  We excluded 
participants with insulin values above clinically realistic values (400pmol/L) or with 
hyperglycaemia or potential type 2 diabetes (defined as glucose values above 7mmol/L).  
High sensitivity C-reactive protein (hs-CRP) was measured by a highly sensitive automated 
micro particle capture enzyme immunoassay (Abbott Laboratories).  Inter- and intra-assay 
CV were <10% throughout the range for all biomarkers.  Systemic inflammation was defined 
as an hs-CRP value ≥3 mg/L.  Data on hs-CRP were available for 1432 of the 1997 
participants who were assessed for insulin resistance. 
 
Peripheral systolic (SBP) and diastolic (DBP) blood pressure were measured by a trained 
nurse or research assistant using an automated cuff sphygmomanometer (OMRON 
HEM713C, Tokyo, Japan) with the participant in the seated position for at least three minutes 
prior to taking three measurements.  Hypertension was defined as a SBP above 140 mm Hg 
and/or diastolic blood pressure above 90 mm Hg and/or use of anti-hypertensive drugs.  
Blood pressure data was available for 1952 (98%) of the participants included in these 
analyses.       
 
Levels of all lipids were measured by using a Cobas Fara machine (Roche Diagnostics).  
High density lipoprotein cholesterol (HDL-C) and triglycerides (TG) were determined by a 
colorimetric enzymatic method.  HDL-C was determined after precipitation of larger particles 
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(chylomicron,VLDL, and LDL) by magnesium and dextran sulfate.  Lipid levels were 
expressed as logTG/HDL-C as this measure has shown to be strongly correlated with 
cardiometabolic risk (12).  Dyslipidemia was defined as HDL-C ≤ 1.3 mmol/L and TG ≥ 1.7 
mmol/L or use of cholesterol lowering drugs.  Data were available for 1845 (92%) of these 
participants.  
  
According to the NCEP ATP III criteria, metabolic syndrome was defined in the presence of 
three or more of the following: glucose ≥6.1 mmol/L, TG ≥1.7 mmol/L, HDL-C ≤1.3 
mmol/L, waist circumference ≥88 cm or elevated blood pressure (SBP ≥130 and/or DBP ≥85 
and/or antihypertensive drug treatment) (13).  Complete data on metabolic syndrome was 
available for 1663 (83%) participants.  
 
Metabolomic analyses 
In a sample of 3299 participants, non-targeted metabolite detection and quantification was 
conducted (Metabolon, Inc. , Durham, NC) on fasting plasma samples using ultra-high 
performance liquid chromatography and gas chromatography mass spectrometry platforms, 
as described previously (14).  Of the metabolites identified, 75 were determined to be 
representative of amino acid metabolism (listed in Supplemental table 1) and were included 
in these analyses (15).      
 
Assessment of dietary intakes 
Participants completed a 131-item validated FFQ (16, 17).  Nutrient values were assigned to 
each item in the FFQ or for mixed dishes a value for each ingredient, using data from UK 
food composition tables (18) .  Amino acid content was derived predominantly using UK 
food composition data with additional data from the US Department of Agriculture if UK 
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data was not available (19, 20).  If the sum of the individual amino acids and the values for 
protein from the latest UK food composition tables differed for a specific food item the 
amino acid values were rescaled to match the most recent protein data (19).  Nutrient intakes 
were calculated as the frequency of each food multiplied by the nutrient content of the food 
for the appropriate portion size (21).  We set quantitative limits based on confidence intervals 
to define dietary under-reporters using values of reported energy intake and total predicted 
energy expenditure (22).  These calculations accounted for the within-subject variation 
inherent in the methods used to assess energy intake and expenditure (23).  It has been shown 
that excluding potential under-reporters can introduce considerable bias into a sample and 
therefore we considered the ratio of energy intake to estimated energy expenditure as a 
covariate in all multivariable models (24). 
  
Assessment of covariates 
Information on smoking, medication use and menopausal status was obtained by standardized 
nurse-administered questionnaire.  Physical activity was classified as inactive, moderate, and 
active during work, home and leisure time using a questionnaire strongly correlated with a 
more in-depth assessment of activity levels in this cohort (25).  The estimated active time per 
week for these physical activity levels is: inactive 16 minutes; light activity 36 minutes; 
moderate activity 102 minutes; and heavy activity 199 minutes (25).  Zygosity was 
ascertained by questionnaire and confirmed via subsequent genotyping as part of genome-
wide association studies (PE Applied Biosystems, Foster City, California).     
      
Statistical analysis  
Firstly, we used all the participants, treating twins as individuals (individual level analysis) 
while accounting for twin-pair clustering.  Data were available for 1997 (61%) of the 3262 
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participants who completed a valid FFQ (960 twin pairs and 77 individuals).  Participants 
were ranked into quintiles of BCAA intake expressed as a percentage of total protein and 
associations with cardiometabolic parameters were determined using ANCOVA.  Prevalence 
ratios for insulin resistance, metabolic syndrome, inflammation and overweight were 
estimated by quintile of BCAA intake using Poisson regression.   
   
In further analyses we excluded singletons from the analyses (n=77) and examined 
associations between BCAA intake, in quintiles, and cardiometabolic variables in models that 
included the twin-pair mean for BCAA intake as follows:  
𝐸(𝑌𝑖𝑗) =  𝛽0 + 𝛽𝑖𝑋𝑖𝑗 +  𝛽𝑡?̅?𝑖 
where 𝑌𝑖𝑗 and 𝑋𝑖𝑗 represent the cardiometabolic (Υ) and BCAA intake variable (X) of twin j 
from family i and ?̅? is the twin-pair mean (26). 𝛽𝑡 can be interpreted as the result of a 1-
quintile increase in the pair-average of BCAA intake on cardiometabolic health with the 
individual intake held fixed (between-pair association).  𝛽𝑖 is the result of a one-quintile 
increase in the individuals BCAA intake on cardiometabolic parameters with the pair average 
held fixed (within-pair association).  Within-pair associations are inherently controlled for 
shared environmental factors and, in MZ pairs, genetic confounding.  
 
All models were adjusted for age (years), current smoking (yes or no), physical activity 
(inactive, moderately active, active), BMI (kg/m2), use of hormone replacement therapy (yes 
or no), use of diabetes or cholesterol lowering drugs (yes or no), use of vitamin supplements 
(yes or no), menopausal status (pre- or post-menopausal), under-reporting (yes or no) and 
intakes of energy (kcal), carbohydrate (g), saturated fat (g), wholegrains (g), alcohol (g), and 
protein (g).  Natural-log-transformed values were used as the distribution of cardiometabolic 
outcome measures were skewed, with the exception of lipid levels expressed as logTG/HDL-
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C.  Values in the text are means or geometric means (95%CI) except for values from within-
pair analyses which are the geometric means expressed as a percentage of the non-
transformed values, calculated as: 
[(𝑒𝑥𝑝𝛽) − 1] ∗ 100 
 
Linear regression was used in multivariable analyses to determine associations between 
BCAA intake and the 75 metabolites associated with amino acid metabolism (15).  A 
separate random intercept model was performed for each metabolite with age, BMI, batch 
effects, family relatedness, smoking status and energy intake included as covariates:   
Υ𝑖 = 𝛽0 + 𝛽𝑖Χ𝑖𝑗 + 𝛾𝑖𝑎𝑔𝑒𝑖𝑗 + 𝛿𝑖𝐵𝑀𝐼𝑖𝑗 + ζ𝑗 + 𝜀𝑖𝑗 
where Yi is the metabolite and Xij is the BCAA intake of twin j from pair i, and ζj is the 
family-specific error component that captures the unobserved heterogeneity or family 
characteristics.   
 
P-values <0.05 were considered statistically significant for all analyses except for the 
metabolomic models where we accounted for multiple testing using Bonferroni correction,  
giving a significance threshold of 6.67x10-4.  Statistical analyses were performed with Stata 
statistical software version 11 (StataCorp, Texas, USA).          
 
Results 
The characteristics, cardiometabolic risk factors and dietary intakes of the study participants 
are shown in Table 1.  BCAAs contributed to 18.1% (SD 0.4 range 16.5 to 20.3) of protein 
intake with leucine (43.7% SD 0.4 range 41.7 to 46.3) contributing more than isoleucine 
(25.9% SD 0.4 range 24.2 to 27.0) and valine (30.4% SD 0.4 range 29.3 to 32.7) to total 
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BCAA intake (data not shown).  Compared to the participants included in the hs-CRP 
analyses (n=1432) those excluded for having missing data (n=565) were significantly 
younger (45.2 y vs. 47.9 y, t = -4.49 P < 0.01) and therefore less likely to be post-menopausal 
(2 = 18.2 P < 0.01) or to take HRT (2 = 8.1 P < 0.01).  These participants also had higher 
saturated fat intakes (27.5 g vs. 26.0 g, t = 2.9 P < 0.01), were more likely to smoke (2 = 5.5 
P = 0.02) and less likely to take vitamin supplements (2 = 6.7 P = 0.01).  There were no 
significant differences between those participants included (n=1972) or excluded (n=205) 
from the body fat analyses (data not shown).    
 
There was a difference in BCAA intake between extreme quintiles of 1.3g or 1.2% of protein 
(Table 2).  In multivariable analyses a higher BCAA intake was associated with a lower 
WHtR (Q5-Q1 = -0.01, P-trend 0.04) and there was a trend towards a lower body weight 
although this finding did not reach levels of statistical significance (Q5-Q1 = 0.7 kg, P-trend 
0.05).  Higher BCAA intake was also associated with significantly lower insulin resistance as 
indicated by lower HOMA-IR (Q5-Q1 = -0.1, P-trend 0.02) and insulin concentrations (Q5-
Q1 = -0.5 µU/mL, P-trend 0.03) in addition to lower hs-CRP levels (Q5-Q1 = -0.3 mg/L, P-
trend 0.01) and lower SBP (Q5-Q1 = -2.3 mm Hg, P-trend 0.01) comparing those in the 
highest and lowest quintiles of intake.    
 
In our cardiometabolic risk factor analyses participants with higher BCAA intake had a lower 
prevalence of overweight, insulin resistance, systemic inflammation, and hypertension 
(Figure 1 and Supplemental table 2).  There was no association between BCAA intake and 
prevalence of metabolic syndrome, dyslipidemia or abdominal obesity.     
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In analyses controlling for genetic and shared environmental confounders in twin-pairs, 
significant within-pair associations between BCAA intake and markers of insulin resistance, 
inflammation and blood pressure were observed. Specifically, a one-quintile higher intake of 
BCAA was associated with lower HOMA-IR (2.1% 95% CI -3.9, -0.2 P=0.03), insulin 
(2.0%, 95% CI -3.8, -0.2 P=0.03) and hs-CRP (7.1% 95% CI -11.7, -2.3 P<0.01).  After 
stratifying by zygosity we observed a greater magnitude of association for MZ than DZ 
twins, suggesting that the associations were free of genetic confounding (HOMA-IR -5.0% 
95% CI -8.1, -1.9 P<0.01; insulin -4.8% 95% CI -7.7, -1.8 P<0.01; hs-CRP -9.7% 95% CI -
17.7, -1.0 P=0.03; diastolic blood pressure -1.2% 95% CI -2.3, -0.1, P=0.04).  No within-pair 
associations were observed for weight status variables or cholesterol levels.  We observed no 
significant associations in our between-twin analyses when all twins were considered 
together or when stratified by zygosity (data not shown).  
 
BCAA intake was unrelated to circulating levels in the 3299 participants for whom data were 
available (leucine β=0.005 95% CI -0.07, 0.05 P=0.91, valine β=-0.01 95% CI -0.06, 0.09 
P=0.76 and isoleucine β=-0.04 95% CI -0.11, 0.04 P=0.35, Supplemental Table 1).  After 
Bonferroni correction, two of the 75 metabolites identified to be representative of amino acid 
metabolism were significantly inversely associated with BCAA intake, alpha-
hydroxyisovalerate (β=-0.15 95% CI -0.23, -0.07 P=2.99x10-4) and trans-4-hydroxyproline 
(β=-0.20 95% CI -0.28, -0.12 P=1.48x10-6).   
 
Discussion  
In the current study, using a co-twin design, significant inverse associations were observed in 
female twins between dietary intakes of BCAA and measures of insulin resistance, 
inflammation and blood pressure, associations that were independent of a wide range of 
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known cardiometabolic risk factors including smoking, physical activity, BMI and 
medication use.  To our knowledge, this was the first study to examine these associations 
within a twin population which provided us with a unique opportunity to control for genetic 
confounding.  With stronger findings observed in MZ compared to DZ twins, these results 
suggest that shared environmental and genetic factors do not confound the reported 
associations.  Additionally, in metabolomic analyses, we identified two metabolites that were 
inversely associated with BCAA intake; alpha-hydroxyisovalerate and trans-4-
hydroxyproline.  Interestingly higher circulating levels of alpha-hydroxyisovalerate have 
previously been associated with greater adiposity and blood pressure and circulating levels of 
trans-4-hydroxyproline have shown to be elevated in patients with dietary-induced non-
alcoholic fatty liver disease, a cardio-metabolic risk factor for the development of diabetes 
(27-29).  We found no association between BCAA intake and circulating levels confirming 
previous findings in children and adding evidence to support the theory that plasma BCAA 
levels are not a direct reflection of diet-derived intakes (30).  
 
Genetic factors are strong determinants of dietary habits and cardiometabolic health, with 
estimates of heritability reported between 43-57% (11, 31).  Our within-twin analysis 
confirmed our individual-level findings for insulin resistance and inflammation but not those 
for measures of weight status which may indicate that previously reported associations 
between BCAA intake and weight status are influenced by genetics or other lifestyle factors 
not considered (6, 32).   We found no associations between BCAA intake and lipid levels or 
prevalence of metabolic syndrome in our individual- or twin-level analyses.  It is noteworthy 
that the prevalence of clinical dyslipidemia and metabolic syndrome were very low in this 
apparently healthy cohort (9%).   
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Our results are consistent with a short-term (2 month) intervention trial which observed 
improvements in insulin resistance and β-cell function in men with chronic liver disease but 
no significant effect on body composition following supplementation with 3.2g of BCAA 
(0.8g valine, 1.6g leucine and 0.8g isoleucine) (33).  Our findings however, only partly 
support those of a longer-term supplementation trial (7.1g leucine for 6 months) in which 
both glycemic control and body composition were not changed in diabetic males (34).  Our 
novel data also provide mechanistic support for the reported association between higher 
BCAA intake (0.9% of protein) and a 43% decreased risk of diabetes in Japanese women 
(35).  Furthermore, our findings are plausible given the findings from mechanistic studies; 
Macotela et al. recently reported, using rodent models, that doubling dietary leucine for eight 
weeks reversed many of the metabolic abnormalities associated with high fat diet-induced 
obesity, improving glucose tolerance, insulin signaling and inflammation in the adipose 
tissue.  Interestingly, they found that serum cholesterol levels were not changed by leucine 
administration (36).  Our associations between BCAA intake and cardiometabolic health 
were independent of total protein intake and it is noteworthy that there were no associations 
between total protein intake and any of the cardiometabolic factors examined in these 
analysis (data not shown).  This suggests an independent effect of BCAA rather than BCAA 
acting as a marker of total protein intake. 
 
Our study results have potential clinical significance.  Previous studies have shown that 
reduced insulin resistance and inflammation is associated with lower rates of obesity, type 2 
diabetes and cardiovascular disease (37).  In our study, the highest quintile of BCAA intake 
compared with the lowest quintile was associated with 19-37% lower insulin resistance, 
inflammation, overweight and hypertension.  The presence of insulin resistance (HOMA-IR 
>2) was previously related to an increased odds ratio of 1.54 (95% CI 0.91–2.62) for 
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coronary artery disease and elevated CRP (hs-CRP > 3mg/L) was associated with odds ratios 
of 1.46 (95% CI 1.05–2.04) for cardiovascular disease and 3.12 (95% CI 1.77-5.48) for type 
2 diabetes (38-40).  Although the associations we observed in absolute terms may be 
considered modest it has previously been shown that small changes in risk factors such as 
cholesterol, blood pressure and obesity are associated with potentially clinically relevant 
changes to cardiovascular risk (41).     
 
To place our findings into context we examined the standardized beta coefficients for the 
HOMA-IR model which allowed us to compare the magnitude of associations for the various 
predictors within our model.  The size of the standardized coefficient for BCAA intake (-0.05 
95% CI -0.09, -0.01) was more than half that of smoking, a major risk factors for poor 
cardiometabolic status, and 1.6 and 7 times greater than alcohol intake and age, respectively.  
The major dietary sources of BCAA in this cohort were milk (16.3% of intake), red meat 
(11.1% of intake), poultry (8.8% of intake) and high fat dairy products (5.8% of intake).  The 
difference in intakes of BCAA between extreme quintiles of intake in the current study was 
1.3 g/day, to incorporate these levels of BCAA into the diet people would need to consume 
either a glass of milk (185g), one small piece of cheddar cheese (20g), one small portion of 
cashew nuts (35g), or approximately one quarter of a beef or salmon steak (28g).  Although 
this establishes that the relationships we have reported are related to dietary achievable 
intakes of BCAA further research is required before recommendations on BCAA intakes in 
relation to metabolic health can be made.   
  
Strengths of the current study include the large sample of well characterised participants and 
the use of the co-twin model which allowed us to examine these associations independently 
of genetic confounding.  It was notable that we excluded participants with high glucose levels 
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(>7mmol/L) and there were low proportion of participants with metabolic syndrome and 
dyslipidemia (<10%), as it is plausible that we would have observed greater associations if 
participants with impaired metabolic function were included.  A further strength was the 
range of robust measures of cardiometabolic status, which included dual-energy X-ray 
absorptiometry measured body composition and HOMA-IR which is a reliable measure of in 
vivo insulin resistance and correlates well with scores obtained from the hyperinsulinemic-
euglycemic clamp technique (42).  There were also limitations.  There is a lack of evidence to 
show the FFQ used in the current study is able to accurately quantify BCAA intake although 
it has the ability to reflect habitual dietary intake and rank participants according to amino 
acid and protein intake (11, 43, 44).  We cannot infer causality from this cross-sectional study 
and therefore intervention studies are needed.  Furthermore, although we adjusted for a range 
of confounders (such as age, smoking, physical activity, BMI, medication use, and intake of 
other nutrients associated with cardiometabolic health), there was still the possibility of 
residual or unmeasured confounding from additional unmeasured factors.  Although we made 
a number of hypothesis-driven comparisons in this study we believe they were justified given 
the novel and exploratory nature of the analyses.     
 
In conclusion, these novel data suggest that habitual intake of BCAA was inversely 
associated with parameters of insulin resistance, inflammation and blood pressure 
independent of shared genetic and common environmental factors.  In addition, from our 
metabolomic dataset we identified two biomarkers of BCAA intake that have previously been 
associated with adiposity, although these findings need to be replicated in other data sets.  
Our results have clinical and public health relevance as our findings were related to dietary 
achievable intakes.  These findings support the hypothesis that BCAA have cardio protective 
effects through improvements in insulin resistance, inflammation and blood pressure and 
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highlight the need for more intervention trials examining dietary attainable levels of BCAA 
and metabolic health. 
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Figure 1:  Prevalence ratios for obesity and cardiometabolic risk factors in the highest 
vs. lowest quintile of BCAA intake in females aged 18-76 y1 
1Values are adjusted prevalence ratios (95% CI), n=1997.  P= P-trend across quintiles of 
intake calculated using ANCOVA.  Prevalence ratios are adjusted for age, smoking, physical 
activity, BMI, HRT, menopausal status, use of diabetes or cholesterol lowering drugs, 
vitamin supplements, under-reporting, and intakes of energy, carbohydrate, saturated fat, 
wholegrains, alcohol and protein.  Overweight and abdominal obesity are not adjusted for 
BMI.  Insulin resistance =  HOMA-IR ≥ 2.5; systemic inflammation = hs-CRP ≥3 mg/L, 
dyslipidemia = HDL-C ≤ 1.3 mmol/L and TG ≥ 1.7 mmol/L or use of cholesterol lowering 
drugs; overweight = BMI ≥ 25 kg/m2; abdominal obesity =  waist to height ratio ≥0.5;  
hypertension = systolic blood pressure ≥140 mm Hg and/or diastolic blood pressure ≥ 90 mm 
Hg and/or anti-hypertensive drug treatment; metabolic syndrome = three of the following risk 
factors, glucose ≥6.1 mmol/L, TG ≥1.7 mmol/L, HDL-C ≤1.3 mmol/L, waist circumference 
≥88 cm or elevated blood pressure (systolic ≥130 and/or diastolic ≥85 and/or 
antihypertensive drug treatment).  Full data is presented in Supplemental table 1.  Subset 
analysis: inflammation = 1432; dyslipidemia = 1845; abdominal obesity = 1828; hypertension 
= 1952; metabolic syndrome = 1663.   
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Table 1: Characteristics of females aged 18 -76 y1  
 Value 
Characteristics  
  Age (y) 41.7 ± 12.1 (39, 56) 
  Zygosity (n % monozygotic) 23.2 (464) 
  BMI (kg/m)2 25.2 ± 4.5 (22.1, 27.3) 
  Current smoker (yes; n %) 17.5 (350) 
  Physically active (yes; n %) 26.7 (533) 
  Hormone replacement therapy use (yes; n %) 17.5 (349) 
  Post-menopausal (yes; n %) 44.7 (893) 
  Diabetes or cholesterol lowering drug use (yes; n %) 1.7 (34) 
  Vitamin supplement use (yes; n %) 53.3 (1064) 
Adiposity and cardiometabolic markers  
  Body fat (% total body mass) 35.0 ± 7.5 (29.8, 40.2) 
  Weight (kg) 66.5 ± 12.1 (57.9, 72.5) 
  Overweight (BMI ≥25) 12.8 (255) 
  Waist to height ratio  0.5 ± 0.1 (0.4, 0.5) 
  Abdominal obesity (waist to height ratio ≥0.5) 39.1 (715) 
  HOMA-IR 1.6 ± 1.6 (0.8, 1.7) 
  Fasting insulin (µU/mL)  7.8 ± 6.8 (4.2, 8.6) 
  Fasting glucose (mmol/L)  4.5 ± 0.5 (4.2, 4.8) 
  Insulin resistance (HOMA-IR ≥2.5) 11.9 (238) 
  hs-CRP2 (mg/L)  2.5 ± 2.4 (0.7, 3.6) 
  Systemic inflammation (hs-CRP ≥3) 31.4 (450) 
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  Lipids (logTG:HDL-C) 0.07 ± 0.34 (-0.16, 0.25) 
  Dyslipidemia (HDL-C ≤1.3 and TG ≥1.7 or statin use) 7.9 (145) 
  Systolic blood pressure (mm Hg) 121 ± 16.6 (109, 131) 
  Diastolic blood pressure (mm Hg) 76.8 ± 11.3 (69, 84) 
  Hypertension (systolic ≥140 or diastolic ≥90 or medicated) 19.7 (379) 
  Metabolic syndrome3 9.1 (152) 
Dietary intake  
  BCAA, % protein/d 18.1 ± 0.4 (17.9, 18.4) 
  Protein, g/d 81.8 ± 22.0 (66.9, 95.6) 
  Energy, kcal/d 1991 ± 534 (1611, 2339)  
  Carbohydrate, g/d 256 ± 76.2 (202, 304) 
  Saturated fat, g/d 26.4 ± 10.5 (18.8, 33.0) 
  Wholegrains, g/d 89.2 ± 78.3 (31.6, 129) 
  Alcohol, g/d 10.1 ± 13.9 (1.2, 13.5) 
  Energy intake: EER 86.4 ± 24.7 (68.7, 102)  
1Values are mean ± SD (IQR) or percentages (frequencies), n = 1997.  BCAA = branched 
chain amino acids; EER = estimated energy requirements; HDL-C = high density lipoprotein 
cholesterol; HOMA-IR = homeostasis model assessment of insulin resistance; hs-CRP = 
high-sensitivity C-reactive protein; TG = triglycerides.  2Subset analysis: hs-CRP = 1432; 
lipids = 1845; body fat = 1792; waist to height ratio = 1828; blood pressure = 1952.  
3Metabolic syndrome was defined as the presence of three of the following risk factors, 
glucose ≥6.1 mmol/L, TG ≥1.7 mmol/L, HDL-C ≤1.3 mmol/L, waist circumference ≥88 cm 
or elevated blood pressure (systolic ≥130 and/or diastolic ≥85 and/or antihypertensive drug 
treatment), n=1663. 
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Table 2: Adiposity and cardiometabolic markers by quintile of BCAA intake in females aged 18-76 y1  
 n= Quintile 1  Quintile 2  Quintile 3 Quintile 4 Quintile 5 P-trend 
BCAA intake (% protein) 1997 17.6 (0.2) 17.9 (0.1) 18.1 (0.1) 18.3 (0.1) 18.7 (0.2) - 
Weight (kg) 1997 65.5 (65.0, 66.1) 65.7 (65.2, 66.3) 65.9 (65.3, 66.4) 65.2 (64.7, 65.8) 64.8 (64.2, 65.5) 0.05 
Body fat (% total body mass) 1792 33.8 (33.2, 34.4) 34.1 (33.6, 34.7) 34.5 (34.0, 35.1) 33.6 (33.1, 34.2) 34.6 (34.0, 35.2) 0.28 
Waist to height ratio 1828 0.49 (0.48, 0.50) 0.49 (0.48, 0.49) 0.49 (0.48, 0.49) 0.48 (0.48, 0.49) 0.48 (0.48, 0.49) 0.04 
HOMA-IR 1997 1.3 (1.2, 1.4) 1.3 (1.2, 1.4) 1.2 (1.2, 1.3) 1.2 (1.1, 1.3) 1.2 (1.2, 1.3) 0.02 
Insulin (µU/mL)  1997 6.6 (6.2, 7.0) 6.5 (6.1, 6.9) 6.2 (5.8, 6.5) 6.1 (5.8, 6.5) 6.1 (5.8, 6.5) 0.03 
Glucose (mmol/L)  1997 4.5 (4.4, 4.6) 4.5 (4.5, 4.6) 4.5 (4.4, 4.5) 4.5 (4.4, 4.5) 4.5 (4.4, 4.5) 0.13 
hs-CRP (mg/L)  1432 1.7 (1.5, 1.9) 1.7 (1.5, 1.9) 1.7 (1.5, 1.9) 1.5 (1.4, 1.7) 1.4 (1.3, 1.6) 0.01 
Lipids (logTG:HDL-C) 1845 0.08 (0.04, 0.11) 0.06 (0.02, 0.09) 0.07 (0.04, 0.11) 0.05 (0.02, 0.09) 0.06 (0.03, 0.10) 0.61 
Systolic blood pressure (mm Hg) 1952 121 (120, 123) 121 (119, 122) 120 (118, 121) 119 (118, 121) 119 (117, 120) 0.01 
Diastolic blood pressure (mm Hg) 1952 76.1 (75.0, 77.3) 76.7 (75.7, 77.8) 75.8 (74.7, 77.0) 75.7 (74.7, 76.7) 75.4 (74.3, 76.4) 0.16 
1Values are adjusted geometric means (95% CI) except for intake values which are unadjusted means (SD) and lipid values which are adjusted 
means (95% CI), n=1997.  Means are adjusted for age, smoking, physical activity, BMI, HRT, menopausal status, use of diabetes or cholesterol 
lowering drugs, vitamin supplements, under-reporting, and intakes of energy, carbohydrate, saturated fat, wholegrains, alcohol and protein.  
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Weight and waist to height ratio are not adjusted for BMI and blood pressure was additionally adjusted for use of anti-hypertensive medication.  
BCAA = branched chain amino acids; HDL-C = high density lipoprotein cholesterol; HOMA-IR = homeostasis model assessment of insulin 
resistance; hs-CRP = high-sensitivity C-reactive protein; TG = triglycerides.   
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Table 3:  Within-pair associations between BCAA intake, adiposity and cardiometabolic markers in female twin pairs aged 18-76 y, 
stratified by zygosity1 
 All twins Monozygotic twins Dizygotic twins 
 n= βi % (95%CI) P= n= βi % (95%CI) P= n= βi % (95%CI) P= 
Body fat (% total body mass) 857 -0.2 (-0.6, 0.1) 0.54 185 -0.5 (-1.1, 0.8) 0.38 672 -0.2 (-0.6, 0.3) 0.71 
Weight (kg) 960 -0.2 (-0.8, 0.4) 0.21 222 -0.4 (-1.3, 0.5) 0.09 738 -0.1 (-0.9, 0.6) 0.41 
Waist to height ratio 879 -0.2 (-0.6, 0.1) 0.21 189 -0.1 (-0.8, 0.6) 0.76 690 -0.3 (-0.8, 0.2) 0.22 
HOMA-IR 960 -2.1 (-3.9, -0.2) 0.03 222 -5.0 (-8.1, -1.9) <0.01 738 -0.9 (-3.1, 1.4) 0.45 
Insulin (µU/mL)  960 -2.0 (-3.8, -0.2) 0.03 222 -4.8 (-7.7, -1.8) <0.01 738 -0.9 (-3.0, 1.2) 0.40 
Glucose (mmol/L)  960 0.0 (-0.4, 0.3) 0.78 222 -0.2 (-0.9, 0.5) 0.58 738 0.0 (-0.4, 0.4) 0.89 
hs-CRP (mg/L)  626 -7.1 (-11.7, -2.3) <0.01 181 -9.7 (-17.7, -1) 0.03 445 -6.6 (-12.1, -0.7) 0.03 
Lipids (logTG:HDL-C) 870 -0.8 (-2.2, 0.6) 0.34 184 -0.9 (-3.1, 1.3) 0.42 686 -0.9 (-2.5, 0.8) 0.32 
Systolic blood pressure (mm Hg) 930 -0.3 (-0.8, 0.2) 0.19 207 -0.9 (-1.9, 0.1) 0.08 723 -0.2 (-0.7, 0.3) 0.48 
Diastolic blood pressure (mm Hg) 930 -0.1 (-0.7, 0.4) 0.67 207 -1.2 (-2.3, -0.1) 0.04 723 0.1 (-0.6, 0.7) 0.83 
1Values are the geometric means (95% CI) with the exception of lipids values which are means (95% CI), expressed as a percentage calculated 
from the β-coefficient given a one-quintile increase in BCAA intake with the twin-pair average held fixed, n= 1920.  Values are adjusted for age, 
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smoking, physical activity, BMI, HRT, menopausal status, use of diabetes or cholesterol lowering drugs, vitamin supplements, under-reporting, 
and intakes of energy, carbohydrate, saturated fat, wholegrains, alcohol and protein.  Weight and waist to height ratio are not adjusted for BMI 
and blood pressure was additionally adjusted for use of anti-hypertensive medication.  HDL-C = high density lipoprotein cholesterol; HOMA-IR 
= homeostasis model assessment of insulin resistance; hs-CRP = high-sensitivity C-reactive protein; TG = triglycerides.  
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